We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inhibition of store-operated Ca<sup>2+</sup> entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.
- Authors
WEI HUANG; CAIPING REN; GUOLING HUANG; JIE LIU; WEIDONG LIU; LEI WANG; BIN ZHU; XIANGLING FENG; JIA SHI; JINLONG LI; XIAOMENG XIA; WEI JIA; JIAWEN CHEN; YUXIANG CHEN; XINGJUN JIANG
- Abstract
Sodium butyrate (NaBu), a histone deacetylase inhibitor, has demonstrated anti-tumor effects in several cancers, and is a promising candidate chemotherapeutic agent. However, its roles in nasopharyngeal carcinoma (NPC), an endemic malignant disease in Southern China and Southeast Asia, has rarely been studied. In the present study, MTT assay, colony formation assay, flow cytometry analysis and western blotting were performed to explore the influence of NaBu on NPC cells and its underlying mechanism. NaBu induced morphological changes and inhibited proliferation in 5-8F and 6-10B cells. MTT assay revealed that NaBu was cytotoxic to 5-8F and 6-10B cells in a dose- and time-dependent manner. Furthermore, flow cytometry analysis revealed that NaBu induced obvious cell apoptosis in 5-8F and 6-10B cells due to the activation of the mitochondrial apoptosis axis. In addition, flow cytometry analysis and western blotting demonstrated that NaBu could enhance the Ca2+ influx by promoting store-operated Ca2+ entry (SOCE) in 5-8F and 6-10B cells. Inhibition of SOCE by specific inhibitors or downregulated expression of calcium release-activated calcium channel protein 1 and stromal interaction molecule 1 could counteract the apoptosis of NPC cells induced by NaBu. Thus, the current study revealed that enhanced SOCE and activated mitochondrial apoptosis axis may account for the mechanisms of cytotoxicity of NaBu in NPC cells, and that NaBu serves as a promising chemotherapeutic agent in NPC therapy.
- Subjects
APOPTOSIS; NASOPHARYNX cancer; CANCER cells; SODIUM butyrate; HISTONE deacetylase inhibitors
- Publication
Oncology Letters, 2017, Vol 13, Issue 2, p921
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2016.5469